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Leishmaniasis is widely regarded as a vaccine-preventable disease, but the costs required to
reach pivotal Phase 3 studies and uncertainty about which candidate vaccines should be
progressed into human studies significantly limits progress in vaccine development for this
neglected tropical disease. Controlled human infection models (CHIMs) provide a pathway
for accelerating vaccine development and to more fully understand disease pathogenesis and
correlates of protection. Here, we describe the isolation, characterization and GMP manu-
facture of a new clinical strain of Leishmania major. Two fresh strains of L. major from Israel
were initially compared by genome sequencing, in vivo infectivity and drug sensitivity in mice,
and development and transmission competence in sand flies, allowing one to be selected for
GMP production. This study addresses a major roadblock in the development of vaccines for
leishmaniasis, providing a key resource for CHIM studies of sand fly transmitted cutaneous
leishmaniasis.
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he leishmaniases represent a group of diseases caused by
infection with various species of the parasitic protozoan
Leishmania. One billion people are at risk of infection
across 98 countries worldwide, with over 1.5 million new cases
and 20,000–40,000 deaths reported each year1,2. The leishma-
niases are vector-borne diseases, each parasite species having co-
evolved for transmission by one or more species of phlebotomine
sand fly3,4. Disease manifestation is intimately linked to the
species of infecting parasite5,6 and may be evident as self-healing
lesions restricted to the site of skin transmission (cutaneous
leishmaniasis; CL), lesions which spread from an initial skin
lesion to involve the mucosae (mucosal leishmaniasis; ML) or
which spread uncontrolled across the body (disseminated or
diffuse cutaneous leishmaniasis; DCL), or as a potentially fatal
systemic disease involving major organs such as the spleen, liver
and bone marrow (kala azar or visceral leishmaniasis; VL)5. In
addition, patients recovering from VL following chemotherapy
often develop a chronic skin condition (post kala-azar dermal
leishmaniasis; PKDL) that can sustain community transmission
of VL7,8. Collectively, the tegumentary forms of leishmaniasis
account for approximately two-thirds of the global disease bur-
den, while VL accounts for most reported deaths1,6. In addition to
the impact of primary disease, recent studies have also empha-
sized the importance of considering the long term sequelae of
leishmaniasis, notably those associated with stigmatization, when
evaluating global burden of these diseases9–11.
The leishmaniases are widely regarded as vaccine-preventable
diseases based on disease natural history, epidemiological data
and studies in experimental models of leishmaniasis (reviewed in
refs. 12–15). Four vaccines for canine visceral leishmaniasis have
reached the market, though with remaining questions about the
extent of clinical versus parasitological protection that they pro-
vide16. To date, no human vaccines have achieved licensure17.
Often cited barriers to vaccine development include limited
investment, with only $3.7 M of new R&D funding globally in
201818, an excess of candidate antigens and delivery systems19,
the questionable predictive capacity of pre-clinical animal
models20,21, lack of good correlates of protection and a defined
target product profile22, the costs and challenge of large-scale
efficacy studies in disease endemic countries coupled with the
high prevalence of asymptomatic infections23,24 and a fragmented
pipeline for translational research25. As has been found with
other diseases26–33, the incorporation of a controlled human
infection model (CHIM) into the vaccine R&D pipeline can
overcome many of these issues.
Artificial human infection (“leishmanization”) with Leishma-
nia had been practiced for centuries by people living in the
Middle East and former Soviet states, where CL is highly ende-
mic. Building on the knowledge that cure from CL engendered
protection against reinfection, scrapings from active lesions were
used to cause disease at a site of choice (e.g. the buttock), so
avoiding the stigmatization associated with CL scars (reviewed in
ref. 34). More defined experimental studies were conducted
sporadically through the 20th century, culminating in a WHO-
sponsored evaluation of the potential for human challenge as a
tool to evaluate vaccines for leishmaniasis, conducted in Iran in
200535. This study employed a L. major strain that had been
produced at GMP and used for previous leishmanization studies.
Results from this study demonstrated a take rate of 86% in pre-
viously non-exposed volunteers. Lesions were <3 cm diameter
and ulcerated in 74% of cases. All lesions self-healed without
treatment between 75 and 285 days after inoculation. In a limited
re-challenge study using the same strain, 0/11 volunteers receiv-
ing leishmanization developed a lesion, compared to 5/5 in non-
leishmanized controls35. Poor viability of the challenge agent and
limited funding opportunities curtailed this programme before it
could be developed further and to date, no defined vaccines have
been tested using this approach.
With the advent of new candidate vaccines in or approaching
the clinic, there is renewed imperative to develop a CHIM for
leishmaniasis. An adenoviral-vectored vaccine (ChAd63-KH) was
found to be safe and immunogenic in healthy volunteers36 and in
PKDL patients (Younnis et al. submitted) and is currently in
Phase IIb as a therapeutic in Sudanese PKDL patients. A live
genetically attenuated L. donovani centrin−/− parasite has shown
efficacy in pre-clinical models37–39 and a L. major centrin−/− 40 is
soon to enter GMP production. An adjuvanted recombinant
polyprotein vaccine (LEISH-F3/GLA-SE) has been progressed to
Phase I41 and a newer derivative (LEISH-F3+/GLA-SE) evaluated
in pre-clinical models21. RNA-based vaccines are also in devel-
opment42. In addition, new knowledge regarding the integral
nature of sand fly transmission to Leishmania infectivity has
emerged in recent years43–45, underpinning the observation that
vaccines inducing protection in mice when infected via needle
inoculation fail to protect against sand fly-transmitted infection46;
hence the need to incorporate vector transmission as part of
a CHIM.
The pathway for development of a CHIM for sand fly-
transmitted leishmaniasis requires three enabling activities: the
identification of an appropriate challenge agent, optimization of
sand fly transmission studies in humans, and patient and public
involvement (PPI). Here, we describe completion of the first of
these steps, namely the isolation, characterization and GMP
production of a new L. major challenge agent.
Results
New clinical strains of Leishmania major. Leishmania major is
endemic in Israel and cases are often associated with travelers
visiting areas of high transmission47,48. Two individuals from
non-endemic areas of central Israel that had self-referred to Sheba
Hospital in early 2019 after developing lesions subsequent to
visiting the endemic region of Negev (Fig. 1a) served as parasite
donors. Donor MRC-01 was a 41-year-old female who developed
a lesion near her lip ~3 months after spending one night out-
doors. She had self-administered topical antibiotics without effect
and presented at clinic ~4 months later with a single erythema-
tous 1.5 cm diameter lesion. Diagnosis for L. major was con-
firmed by PCR and she was treated with intra-lesional sodium
stibogluconate (SSG) on two occasions ~4 weeks apart. Her lesion
fully resolved with minimal scarring by 3 months post treatment
onset (Fig. 1b). Donor MRC-02 was a 22-year-old male who
developed two papules on his shin ~2 months after hiking in the
Negev. He attended clinic 3 months later with two ~1.5 cm dia-
meter ulcerated lesions on the shin and a very small non-
ulcerated lesion on his neck. He was diagnosed positive for L.
major by PCR but refused treatment. His lesions fully resolved
~3–4 months later with scarring (Fig. 1c). Both donors were
negative for HIV, HTLV-1, HBV and HCV, and at 18-month
follow-up, neither reported any reactivation of their lesion(s) or
other unexpected clinical events related to their leishmaniasis.
Whole-genome sequencing of parasite strains from patients
MRC-01 and MRC-02. Parasites were isolated from slit skin
preparations and diagnosis of L. major infection confirmed by
PCR and RFLP analysis. The strains were designated as L. major
MHOM/IL/2019/MRC-01 and L. major MHOM/IL/2019/MRC-
02 (herein referred to as L. majorMRC-01 and L. majorMRC-02,
respectively). Parasites were minimally cultured in GMP grade
media to retain infectivity and multiple vials frozen at P1 as a seed
bank and screened negative for mycoplasma. The seed stock was
redistributed under dry ice using a commercial shipping agent.
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To confirm genetic identity and establish baseline sequence
data, whole-genome sequencing was performed using Illumina
NextSeq deep sequencing. Sequence data for L. major MRC-01
and L. major MRC-02 has been deposited at GenBank. A
phylogeny tree was developed using all available whole-genome L.
major sequences from around the world with L. major Friedlin
strain from Israel used as reference (Fig. 2a). This analysis shows
a geographical clustering of genome sequences and confirms that
L. major MRC-01 and L. major MRC-02 are closely related to
other L. major strains derived from Israel while being distinct
from each other. Next, sequence alignment was performed to
identify the location of single nucleotide polymorphisms relative
to the reference Friedlin strain, using DNA from early culture
passage L. major MRC-01 and L. major MRC-02 (grey lines,
Fig. 2b). Both strains had a number of homozygous SNPs
compared to the reference Friedlin strain in all 36 chromosomes
(Fig. 2b, inner two rings). Similarly, the SNP fingerprint of L.
major MRC-01 compared to L. major MRC-02 also reveal these
are genetically distinct strains consistent with the phylogeny tree.
We also compared whole-genome sequences from L. major
MRC-02 before and after a single passage in BALB/c mice (see
below). Compared to early culture parasites (pre-infection), the
SNP fingerprint of the BALB/c passaged parasites (post-infection)
was nearly identical (Fig. 2b, outer two rings). Only three
additional polymorphisms were identified in parasites recovered
following in vivo passage, and all were heterozygous SNPs in
homopolymer stretches in non-coding regions (Supplementary
Fig. 1a, b). In addition, we found no significant copy number
variation (CNV) differences at the gene or chromosome level
between the genomes from L. major MRC-02 (pre, culture only)
and L. major MRC-02 (post, in vivo infection) parasites
(Supplementary Fig. 2). These observations confirm that L. major
MRC-01 and L. major MRC-02 are closely related to strains
previously isolated in Israel, are genetically distinct from each
other and that there was no selection for genomic mutations or
CNVs following L. major MRC-02 infection in BALB/c mice.
Leishmania RNA viruses (LRV) have been demonstrated in
various Leishmania species: LRV1 in L. (Viannia) braziliensis and
L. (V.) guyanensis, and LRV2 in L. aethiopica, L. infantum, L.
major and L. tropica. RNA was isolated from early passage L.
major MRC-01 and L. major MRC-02, and tested for LRV2 by
RT-PCR49. L. aethiopica LRC-L494, previously shown to contain
LRV2, was used as a positive control. Both L. major strains were
negative for LRV2 (Supplementary Fig. 3).
In vitro and in vivo characterization and drug sensitivity of L.
majorMRC-01 and L. majorMRC-02. Prior to in vivo infectivity
studies, each strain was evaluated for growth under standard
in vitro conditions. Both strains showed similar in vitro growth
curves, with characteristic progression through logarithmic and
stationary phases of growth (Fig. 3a). Metacyclic promastigotes
(Fig. 3b) were isolated by negative selection using PNA50 and
used for infectivity studies in mice. To confirm in vivo infectivity
and assess sensitivity to paromomycin (PM), a standard drug
used for the treatment of CL51, we used susceptible BALB/c mice
infected subcutaneously in the rump with ~106 purified meta-
cyclic promastigotes (Figs. 3 and 4). Mice were randomized to
receive PM (50 mg/kg i.p. daily for 10 days), with treatment
starting when individual lesion size was 3–4mm in diameter.
Both strains induced lesions in BALB/c mice (Fig. 3c, f). In the
absence of treatment, all infected mice progressed to the pre-
determined endpoint (8 mm average diameter, <10 mm in any
direction) or showed progressing disease at the experimental
endpoint of 70 days post infection. However, L. major MRC-02
lesions developed more rapidly and in a more consistent manner.
For example, median time to develop a lesion >2 mm was 37.5 vs.
21.0 days, for L. major MRC-01 and L. major MRC-02, respec-
tively (ratio 1.786, 95% CI of ratio 0.96 to 3.32; p < 0.0001, Fig. 3d,
g and Supplementary Fig. 4). All mice responded well to PM
treatment, with a reduction in lesion size that often reached the
limits of detection within the 10-day treatment window (Figs. 3e,
Fig. 1 Clinical characteristic of patient lesions. a Negev region of Israel (red). Source: Israel location map.svg NordNordWestderivative work: יקנא‘גיקיו ,
CC BY-SA 3.0 https://creativecommons.org/licenses/by-sa/3.0, via Wikimedia Commons. b Donor MRC-01 lesion photographed ~3 months after
treatment onset, showing full resolution of the lesion near the corner of the mouth, with minimal scarring. c Donor MRC-02 lesions photographed
~9 months after travel to the endemic region, showing healing without treatment.
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Fig. 2 Characterisation of L. major MRC-01 and L. major MRC-02 by whole-genome sequencing. a Phylogeny tree developed using all available whole-
genome sequences for L. major from different parts of the world and the location of the L. major MRC-01 and L. major MRC-02 strains. The phylogeny tree
was constructed using the L. major Friedlin strain as the reference strain. b Alignment map for L. major chromosomes 1–36. Grey bars represent location of
homozygous single nucleotide polymorphism (SNPs) and indels where there are differences between L. majorMRC-01, L. majorMRC-02 and L. majorMRC-
02 after passage infection in BALB/c mice) and the reference strain L. major Friedlin. Red bars indicate chromosomal location of SNPs/indels differences
between L. major MRC-02 (pre-infection) and the L. major MRC-02 (post-infection).
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h and 4a–d). Real-time PCR quantification of parasite kDNA in
the lesion indicated that PM treatment reduced parasite load for
both strains by >99% (Fig. 4e). Thus, while both strains are
capable of causing lesions in BALB/c mice which can be cured
using PM, L. major MRC-02 demonstrated more rapid and
reproducible lesion development.
Parasite development in the sand fly vector. To determine
whether L. major MRC-01 and L. major MRC-02 were fully
competent for sand fly transmission, we first conducted artificial
membrane feeding experiments using two vector species, Phle-
botomus papatasi and P. duboscqi. Experimental infections indi-
cated that both strains developed well in the two sand fly species
(Fig. 5a, b), producing high infection rates (100% of sand fly
females infected by day 3 post blood meal (PBM), >75% at days 6
and 15 PBM). In P. duboscqi, development was more vigorous,
with parasite escape from the peritrophic matrix and colonization
of the thoracic midgut, cardia and in some cases the stomodeal
valve by day 3 PBM. In contrast, in P. papatasi the first coloni-
zation of the stomodeal valve was not observed until day 6 PBM
(Fig. 5c, d). Nevertheless, by day 15 PBM, both sand fly species
had supported full development of parasites, with heavy parasite
loads in the thoracic midgut and colonization of the stomodeal
valve in all the female sand flies infected with both L. major
strains.
To more precisely quantify parasite load at each morphological
stage, exact numbers of procyclic and metacyclic forms in
infected sand fly females were counted using a Burker chamber.
The differences between Leishmania strains were not significant,
indicating that both vectors were capable of supporting parasite
development. There was a trend for greater numbers of
metacyclic parasites in sand flies infected with L. major MRC-
02 at day 3 PBM, but this was not apparent by day 15 PBM, with
metacyclic numbers ranging from 200 to 258,000 per sand fly
(Fig. 6 and Supplementary Data 1). Given recent data suggesting
that additional blood meals may serve to enhance the develop-
ment of metacyclics45, we conducted a pilot experiment in which
we provided sand flies either one additional blood meal on an
uninfected BALB/c mouse at day 6 or two additional blood meals
at day 6 and day 12 PBM. Under the conditions used, we found
no significant differences in metacyclic numbers in P. duboscqi
infected with either L. major strain using these different feeding
conditions (Supplementary Data 1). Although both vector species
could therefore be suitable for use in a CHIM, the additional
robustness of P. duboscqi, and a trend towards more permissive
parasite development (ref. 52 and this paper) favour use of this
species.
To evaluate whether expansion under GMP conditions might
affect parasite development, we repeated these experiments using
parasites expanded as a research bank (RB) under conditions
identical to that for proposed GMP manufacture. Given the data
above, we limited these experiments to P. duboscqi given a single
infectious blood meal by membrane feeding. As before, both L.
major strains produced 100% infection rates in sand fly females
on day 3 PBM, with >80% late-stage infections on day 6 and day
15 PBM. At day 3 PBM, 14% and 43%, respectively, of females
infected with L. major MRC-01 and L. major MRC-02 had
parasites located at the stomodeal valve. By day 15 PBM, thoracic
midguts were filled with high numbers of parasites and the
stomodeal valve was colonized in all the females infected with
both strains, though heavier infections developed in sand flies
Fig. 3 Growth characteristics and drug sensitivity of L. major MRC-01 and L. major MRC-02. a Growth curves for L. major MRC-01 and L. major MRC-02
in vitro. Representative of one experiment from two performed. b Photomicrographs of purified PNA-negative metacyclics of L. major MRC-01 (top) and L.
major MRC-02 (bottom) from stationary phase cultures shown in (a). c–h In vivo lesion development in BALB/c mice following subcutaneous infection
with 106 metacyclics of L. major MRC-01 or L. major MRC-02 in the presence or absence of 50mg/kg paromomycin (PM) i.p. daily for 10 days. Treatment
was initiated when lesion diameter reached 3–4mm and mice were killed if lesion size exceeded 9–10 mm in any one direction. Data are presented in
aggregated form (c, f) normalised to the day of treatment initiation (shown as dotted vertical line) and as a timeline for individual mice receiving vehicle
alone (d, g) or PM treatment (e, h). Data are derived from two independent experiments with 9 mice per group for L. major MRC-01 with and without
treatment and L. major MRC-02 with treatment and n= 10 mice for L. major MRC-02 without treatment. Data are shown as mean ± SD. Data points within
horizontal shaded area represent lesion was palpable but not measurable at <1 mm diameter. Source data are provided as a Source data file.
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infected with L. major MRC-02 (Supplementary Fig. 5). Thus, the
limited expansion required to generate a GMP parasite bank does
not negatively impact on parasite development in sand flies.
Transmission of L. major MRC-01 and L. major MRC-02 to
mice by sand fly bite. Ten P. duboscqi females infected by L.
major MRC-01 or L. major MRC-02 were allowed to feed on
anaesthetized BALB/c mice on day 15 post BM. Immediately post
feeding, six ear samples per each strain were taken for determi-
nation of transmitted parasite number using qPCR. Positivity
rates were 5/6 and 6/6 for L. major MRC-01 and L. major MRC-
02, respectively, and numbers of parasites per ear varied from 0 to
Fig. 4 Response of BALB/c mice infected with L. majorMRC-01 and L. majorMRC-02 to paromomycin treatment. Representative photographs of BALB/
c mice infected with L. major MRC-01 (a, c) and L. major MRC-02 (b, d) in absence of treatment (a, b) and at the end of 10 days paromomycin treatment
(c, d). e Parasite loads in lesions of mice treated with paromomycin (PM) or vehicle (PBS), as determined by qPCR. Data are derived from two independent
experiments with 9 mice per group for L. majorMRC-02 with and without treatment and L. majorMRC-01 with treatment and n= 8 mice for L. majorMRC-
01 without treatment. Data are shown as violin plots truncated at the max/min values, with median (black line) and quartiles (red line) and individual data
points indicated. Data comparing with and without treatment were analysed using a two-sided Mann–Whitney test, with p values as indicated. Source data
are provided as a Source data file.
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7240 and from 92 to 5670, respectively, for the two strains (Fig. 7a
and Supplementary Table 1). The average numbers of transmitted
parasites did not differ significantly between the two groups.
An independent group of mice was followed to monitor lesion
development. Three weeks p.i., only ear swelling was observed in
mice bitten by sand flies infected with L. major MRC-01, whereas
lesions had developed in 3/5 mice exposed to sand flies infected
with L. major MRC-02. At the end of the experiment on week 6
p.i., all five mice bitten by L. major MRC-02 infected flies showed
presence of skin lesions while lesions appeared only in a half of
mice (3/6) bitten by L. major MRC-01 infected flies (Fig. 7b,
Supplementary Table 1 and Supplementary Fig. 6). Determina-
tion of parasite load by qPCR at 6 weeks p.i. indicated a trend
towards higher numbers of parasites in mice infected with L.
major MRC-02 (P= 0.08, Fig. 7c). Of note, two mice exposed to
sand flies infected with L. major MRC-01 hosted significant
numbers of parasites in the ear (2.82 × 105 and 6.44 × 105) despite
the absence of lesions (Supplementary Table 1). Hence, L. major
MRC-02 produces rapid and reproducible lesions in mice after
sand fly transmission.
GMP production of L. major MRC-02. A GMP clinical lot of L.
major MRC-02 was produced under contract directly from P1
passage stocks using static T-flask cultures. The clinical lot
comprises ~600 vials, each vial containing 2 × 107 mid-log L.
major MRC-02 in culture media. Vials are stored at −145 ± 10 °C
and we expect shelf life to exceed 5 years. An initial 2 years
stability study will be performed at the Vibalogics manufacturing
site. Release testing of the batch was discussed and agreed with
the UK Medicines and Healthcare products Regulatory Agency
(MHRA) and comprises identity (PCR), resuscitation (indicating
growth), sterility, endotoxin and pH. We estimate conservatively
that in a sand fly CHIM, after retention for stability studies, this
clinical lot will be sufficient for challenge of at least 1200
volunteers. Seed stocks are available for further GMP runs as
required.
Discussion
Controlled human challenge is increasingly viewed as being on
the critical path for vaccine development, allowing an early
demonstration of efficacy and in combination with appropriately
designed Phase I trials, rapid selection/de-selection of candidate
vaccines53. We have therefore sought to develop a new CHIM,
based on best practices derived from other models. Three ques-
tions influenced our approach to developing a challenge agent,
namely which (i) parasite species, (ii) challenge route and (iii)
manufacturing standard?
Addressing the first question, L. major, the causative agent of
Old World CL lends itself to development as a human challenge
agent on a number of counts. First, unlike other species causing
CL, e.g. L. tropica, L. mexicana or L. (Viannia) braziliensis and L.
(V.) guyanensis, where systemic or metastatic spread is commonly
documented, lesion development following L. major infection is
usually localised to the site of sand fly transmission and is most
commonly self-healing5. Numerous barriers to developing a
CHIM model of CL using existing L. major strains were identi-
fied, including limited information on the provenance of parasites
held in depositories or in use in research laboratories. Although
CHIM studies per se are not under formal regulatory control in
the UK, informal advice from the MHRA emphasised the
importance of understanding the clinical history of the challenge
agent donor, donor status with regard other human infectious
agents (e.g. HIV) and the need to ensure absence of contact with
bovine sera potentially contaminated with agents known to cause
transmissible spongiform encephalopathies. In the case of Leish-
mania, passage history also represents an additional, but often
Fig. 5 Qualitative analysis of L. major MRC-01 and L. major MRC-02 development in sand flies. At the days indicated post blood meal (PBM), engorged
P. duboscqi (dub) and P. papatasi (pap) were dissected and parasite development was assessed. Percentage of flies infected with L. majorMRC-01 (a) and L.
major MRC-02 (b) based on assessment of intensity of infection. Development of L. major MRC-01 (c) and L. major MRC-02 (d) as assessed by location
within the gut; endoperitrophic space (ES), anterior midgut (AMG), thoracic midgut (TMG) cardia and stomodeal valve (SV). Data are pooled from three
independent experiments and are shown as frequency of total number of sand flies dissected. Number of sand flies dissected is shown above each bar.
Source data are provided as a Source data file.
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poorly defined, variable that governs infectivity54,55. Hence, two
fresh strains were obtained from donors with documented clinical
histories and for which we could ensure complete traceability of
parasite culture history.
We conducted whole-genome sequencing to establish baseline
characteristics and to assess genetic changes occurring after
passage in animals. The two parasite strains we examined were
genetically distinct, but no features were identified that directly
pertain to their potential value as a CHIM agent, given that
relatively little is known about the genetic nature of virulence in
Leishmania parasites. While virulence factors/pathways have been
identified in various species, including gp63, lipophosphoglycan,
exosome production, proteases and many others56, how these
vary across species or strains and associate with different clinical
presentations is poorly defined57. Symbiotic leishmaniaviruses
have been associated with enhanced host type I interferon
responses and contribute to the metastatic potential in L. Viannia
species58. Although Leishmaniavirus has been detected at lower
frequency in Old World L. major strains59,60, there is no con-
clusive data to suggest an involvement in pathogenesis and
treatment failure. In Iranian cases, L. major infection was not
influenced by the presence or absence of LRV261. In any event,
both L. major MRC-01 and L. major MRC-02 were demonstrated
to be negative for LRV2.
The classical BALB/c mouse model was used to evaluate in vivo
infectivity and drug sensitivity to paromomycin, an often used
drug for the treatment of CL51,62. Parasite development in two
species of sand fly, both natural vectors of L. major confirmed full
Fig. 6 Quantitative analysis of L. major MRC-01 and L. major MRC-02 development in sand flies. At the days indicated PBM, the number of L. major
MRC-01 (blue) and L. major MRC-02 (yellow) parasites in engorged sand flies was quantified. a–c Parasite loads in sand flies at day 3 PBM. d–f, Parasite
loads in sand flies at day 6 PBM. g–i Parasite loads in sand flies at day 15 PBM. Data are shown for all parasites (all forms, a, d, e) and separately for
procyclics (b, e, h) and metacyclics (c, f, i). Data are presented as violin plots truncated at the max/min values, with median (black line) and quartiles (red
line) indicated and reflect counts obtained from 9 to 25 individual sand flies of each species dissected per time point for each infection. Source data and
additional data can be found in Supplementary Data 1.
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life cycle completion, including transmission to mice. The latter
experiments also pertain directly the second question, route of
challenge agent delivery. Vector transmission has been performed
for other CHIMs33,63, and though this approach introduces
potential confounding factors such as variability in infectious
dose and “take rate” compared to needle injection, this needs to
be weighed against the added value of such a model. For leish-
maniasis, the body of evidence indicating a synergistic role of
sand fly salivary components and parasite secretory products in
promoting infectivity43,44,64,65 coupled with the value of sand fly
challenge in identifying vaccine candidates20,21,46,66 together
make a compelling case to proceed with a natural challenge
model. The results of a study to optimise a human biting protocol
using uninfected sand flies (https://www.clinicaltrials.gov/ct2/
show/NCT03999970) and the results of our public involvement
activities related to this study will be reported elsewhere.
Finally, we considered whether manufacture should be to GMP
or GMP-like, as proposed by others. As it is not possible to
generate sand flies that are “GMP”, it might have been argued
that GMP-like would be sufficient for our purposes. However,
given the limited additional costs of producing a clinical lot to
GMP and that this leaves open the possibility for direct needle
challenge or for any future change in the regulatory framework,
we chose to adopt full GMP production of the clinical lot.
We selected L major MRC-02 as the challenge agent for GMP
production based on an assessment of risk vs reproducibility for
participants enrolled in future CHIM studies. The greater con-
sistency in take rate by both needle and sand fly transmission and
more rapid lesion development of L. major MRC-02 compared to
L. major MRC-01 has an important bearing on the conduct and
management of clinical studies as well as significantly decreasing
the number of participants required and the duration of clinical
monitoring. For example, in a simple two-arm (placebo vs. vac-
cine) trial with 90% power to detect a dichotomous outcome
(lesion vs. no lesion) at a p value of 0.05 and with vaccine efficacy
of 60%, a CHIM with 95% take rate would require 24 partici-
pants. In comparison, if the take rate was only 60%, the same
study would require 74 participants. As additional parasitological
and clinical data become available from our early studies using
this CHIM model (see below), alternative end points to lesion
development may also become valuable as indicators of vaccine
efficacy in humans. For example, reducing parasite burden in the
skin might impact transmission competence67 and/or reduced
lesion size or rate of evolution may have some quality of life
benefit9. The GMP clinical parasite bank we have generated is
supported by a comprehensive data package (as described here)
and should be sufficient to conduct CHIM studies in >1200
individuals by sand fly transmission. While manufacture was not
of the scale associated with development of for example virally-
vectored vaccines, it balances yield with the desire to limit in vitro
parasite expansion and should serve as a key resource for several
years to come.
This study has some limitations. L major was chosen as the
challenge agent as this represents the species with most limited
clinical severity. While the use of a L major CHIM would clearly
inform the development of prophylactic vaccines against Old
World CL, the degree to which this data could be extrapolated to
protection against other species, for example L. donovani a cau-
sative agent of VL is untested currently. Epidemiological data has
suggested68 and experimental evidence supports69–71 some degree
of cross-protection between parasites causing CL and VL, including
following vaccination. It is reasonable to suggest therefore that
successful protection following vaccination in a L. major CHIM
would provide highly encouraging albeit not definitive evidence to
support the development of vaccines against VL or other forms of
CL. Additional limitations of the current study are that it is not
possible to accurately predict how infectivity in mice will translate
to infectivity in humans and that it is not possible to quantify
parasite load in infected sand flies prior to use in a transmission
study. To mitigate against these factors, in addition to monitoring
parasite load in replicate cohorts of flies alongside those used for
human infections studies, we have proposed an adaptive clinical
trial design as outlined elsewhere (https://clinicaltrials.gov/ct2/
show/NCT04512742). Following ethical approval, we will initially
evaluate the frequency of parasitologically-confirmed lesions (take
rate), rate of lesion development and parasite load in six volunteers
following exposure to five P. dubosqi infected with L. major MRC-
02. As required, the adaptive design allows for variation in the sand
fly species, the number of infected sand flies and the biting time.
Robust monitoring and early lesion excision will further mitigate
against the development of severe disease. The aim of our initial
studies will be to optimise the CHIM model and inform the design
of subsequent clinical trials employing controlled human infection
as a measure of vaccine efficacy. These studies will also provide for
detailed mechanistic insights into the early evolution of a primary
CL lesion.
Methods
Ethics statement. All human studies were conducted in accord with the
Declaration of Helsinki. Ethical approval was obtained from the Helsinki Com-
mittees of Hebrew University (0400-18-SOR) and The Chaim Sheba Medical
Centre (5658-18-SMC) and the University of York Dept. of Biology Ethics
Fig. 7 Transmission of L. major MRC-01 and L. major MRC-02 to BALB/c mice by sand fly bite. a Parasites loads per ear determined by qPCR
immediately post bite. Data are shown as violin plot for n= 6 ears per parasite strain. Additional data found in Supplementary Table 1. b Photographs of ear
lesions in individual mice 6 weeks post exposure to sand flies infected with L. major MRC-01 and L. major MRC-02. For time-course photographs, see
Supplementary Fig. 6. c Parasite loads determined at 6 week post exposure to infected bites. Data are shown as violin plot for n= 5 (L. majorMRC-02) or 6
(L. major MRC-01) ears per parasite strain. Data are derived from a single transmission experiment. Source data are provided as a Source data file.
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Committee. Informed consent was obtained from patients with PCR-confirmed
leishmaniasis for parasite isolation and subsequent use of these parasites in the
development of a human challenge model. Animals were maintained and handled
at Charles University and the University of York in accordance with institutional
guidelines and national legislation (Czech Republic: Act No. 246/1992 and 359/
2012 coll. on Protection of Animals against Cruelty in present statutes at large; UK:
Animals (Scientific Procedures) Act 1986). All the experiments were approved by
(i) the Committee on the Ethics of Laboratory Experiments of the Charles Uni-
versity in Prague and were performed under permit from the Ministry of Educa-
tion, Youth and Sports of the Czech Republic (MSMT-28321/2018-6), and (ii) The
University of York Animal Welfare and Ethics Review Board and performed under
Home Office license (PPL P49487014).
Mice and parasites. Adult specific pathogen-free BALB/c mice between 8 and
12 weeks old were used in all experiments reported here and were obtained from
either AnLab s.r.o (Prague) or Charles River UK (York). Mice were maintained in
individually ventilated cages with food and water ad libitum and a 12 h light/12 h
dark photoperiod in rooms maintained at 56% humidity, 20–21 °C. Two new
strains, L. major MHOM/IL/2019/MRC-01 and L. major MHOM/IL/2019/MRC-
02 (herein referred to as L. major MRC-01 and L. major MRC-02), were obtained
from patient lesions by culturing in 1 ml Schneider’s Drosophila medium (Cat. No.
21720024, Gibco) containing 20% foetal bovine serum (Australian origin, Cat. No.
10101145, Lot No. 1951998S, Gibco) at 26 °C. Antibiotics were not included in the
medium. The cultures were positive for promastigotes after 9 and 13 days,
respectively. The parasites were further expanded and cryopreserved after one and
two passages. For freezing, parasites (2 × 107 cells/vial) were suspended in
Schneider’s Drosophila medium containing 30% foetal bovine serum and 6.5%
DMSO and transferred to a Mr. Frosty box at −80 °C.
Parasite sequencing and analysis. DNA from promastigote cultures was
extracted using a DNeasy column according to manufacturer’s instruction (Qia-
gen). PCR-free library preparation (Lucigen) and NextSeq 500 sequencing (Illu-
mina) was performed at Genome Quebec. Raw reads were processed as
described72. Briefly, Illumina paired reads were aligned to the reference L.major
Friedlin reference genome sequence obtained from TriTrypDB73 using the
Burrows-Wheeler Aligner (version 0.7.17)74, file formats transformed using sam-
tools (version 1.10), and variant calling was done with VarScan2 (version 2.4.3)75
to generate VCF files. Per sample candidate SNP were called by VarScan2 with a
minimum coverage of 0.4× mean genome coverage, a minimum alternate allele
frequency of 20% (read/read), a minimum average base quality of 15 across the
reads and a 90% significance threshold. For phylogeny generation, additional
sequences obtained from GenBank from whole-genome sequencing projects of L.
major were also processed and aligned along with L. major MRC-01 and L. major
MRC-02 strains. Polymorphisms and copy number variant were plotted using
circos76 and inspected manually using the Integrative Genomics Viewer77.
Homozygous SNP comparisons of L. major MRC-01 and L. major MRC-02 to the
L. major Friedlin strain were analysed and reported.
L. major strains were tested for the presence of LRV2 by RT-PCR using the
primers LRV F-HR (5′-tgt aac cca cat aaa cag tgt gc-3′) and LRV R-HR (5′-att tca
tcc agc ttg act ggg-3′)78. RNA was purified from L. major MRC-01, L. major MRC-
02 or L. aethiopica (MHOM/ET/1985/LRC-L494) using the TRI reagent (Sigma-
Aldrich) according to the manufacturer’s instructions. The latter strain was used as
a positive control for LRV2. cDNA was synthesis using the Transcriptor Universal
cDNA Master Kit (Sigma-Aldrich) with random hexamer primers. Each PCR
reaction (25 μl) contained 5 μl cDNA, 10 μM each primer and 10 μl master mix
(PCR-Ready High Specificity, Syntezza Bioscience); and were carried out as follows:
Initial denaturation 95 °C for 2 min, 35 cycles at 95 °C for 20 s, annealing at 55 °C
for 40 s, extension at 72 °C for 40 s and final extension at 72 °C for 5 min.
Amplicons were analysed on 1.5% agarose gels.
In vivo infectivity by needle challenge. BALB/c mice were infected s.c. in the
shaved rump with 100 µl saline containing 106 metacyclic promastigotes, selected
from stationary phase cultures using PNA agglutination50. Lesion development was
monitored every 2–3 days until patency and daily thereafter. Measurements were
performed in two directions using a dial caliper and the mean (8 mm) and max-
imum single (10 mm) diameter used to evaluate when mice had reached their
clinical endpoint. Lesions were collected post mortem, amastigotes allowed to
transform into promastigotes (P0) and then frozen as a stock culture (P1) for
subsequent sequence analysis (as above). For drug treatments, mice reaching a pre-
determined cut-off of 4 mm were randomized (n= 9–10 per group) to receive
either saline or paromomycin (50 mg/kg, i.p. daily for 10 days). Treated mice were
killed at day 10 post treatment for evaluation of parasite load by qPCR for kine-
toplastid DNA (see below).
Sand fly colonies and sand fly infections. The colonies of P. duboscqi and P.
papatasi (originating in Senegal and Turkey, respectively) were maintained in the
insectary of the Department of Parasitology, Charles University in Prague, under
standard conditions (26 °C on 50% sucrose, humidity in the insectary 60–70% and
14 h light/10 h dark photoperiod)79. The sand fly colonies have been screened by
RT-PCR and found to be negative for Phleboviruses (including Sandfly Fever
Sicilian Virus group, Massilia virus and Toscana Virus) and Flaviviruses (targeting
a conserved region of the NS5 gene). Only female sand flies are used in
experiments.
Promastigotes from log-phase cultures (day 3–4 in culture) were washed twice
in saline and resuspended in heat-inactivated rabbit blood at a concentration of 1 ×
106 promastigotes/ml. Sand fly females (5–9 days old) were infected by feeding
through a ethanol-sterilized chick-skin membrane (BIOPHARM) on the
promastigote-containing suspension. Engorged sand flies were separated and
maintained under the same conditions as the colony. On day 3, 6 and 15 post
bloodmeal (PBM) sample sand flies were dissected and digestive tracts examined by
light microscopy. Five locations for Leishmania infection were distinguished:
endoperitrophic space (ES), abdominal midgut (AMG), thoracic midgut (TMG),
cardia (CA) and the stomodeal valve (SV). Parasite loads were estimated by two
methods: (i) infections were qualitatively assessed in situ as light (<100 parasites
per gut), moderate (100–1000 parasites per gut) and heavy (>1000 parasites per
gut)80; (ii) infections were quantitatively assessed by transferring each gut into
100 μl of 0.01% formaldehyde solution, followed by homogenization and counting
using a Burker chamber. Leishmania with flagellar length <2 times body length
were scored as procyclic forms and those with flagellar length >2 times body length
as metacyclic forms81.
Sand fly to mouse transmission experiments. For transmission experiments,
BALB/c mice were anaesthetized with ketamin and xylazine (62 mg and 25 mg/kg).
Sand flies infected for 15 days (as above) were placed into small plastic tubes
covered with the fine mesh (10 females per tube) and the tubes were held on the ear
pinnae of anaesthetized mice for 1 h. Engorged sand fly females were immediately
dissected for microscopical determination of infection status (as described above).
One group of mice was euthanized immediately post transmission and a second
group of mice was followed for a period of 6 weeks p.i.
Determination of parasite load in tissues. Sand fly-exposed ear pinnae were
dissected and stored at −20 °C. Extraction of total DNA was performed using a
DNA tissue isolation kit (Roche Diagnostics, Indianapolis, IN) according to the
manufacturer’s instructions. Lesions from needle challenge were dissected and
stored at −80 °C. Extraction of total DNA was performed using DNeasy tissue
isolation kit (Qiagen) according to the manufacturer’s instruction. Parasite quan-
tification by quantitative PCR (qPCR) was performed in a Bio-Rad iCycler & iQ
Real-Time PCR Systems using the SYBR Green detection method (SsoAdvanced™
Universal SYBR® Green Supermix, Bio-Rad, Hercules, CA). Primers targeting 116
bp long kinetoplast minicircle DNA sequence (forward primer (13A): 5′-GTG
GGGGAGGGGCGTTCT-3′ and reverse primer (13B): 5′-ATTTTACACCAACCC
CCAGTT-3′) were used82. One microlitre of DNA was used per individual reac-
tion. PCR amplifications were performed in triplicates using the following condi-
tions: 3 min at 98 °C followed by 40 repetitive cycles: 10 s at 98 °C and 25 s at 61 °C.
PCR water was used as a negative control. A series of 10-fold dilutions of L. major
promastigote DNA, ranging from 5 × 103 to 5 × 10−2 parasites per PCR reaction
was used to prepare a standard curve. Quantitative results were expressed by
interpolation with a standard curve. To monitor non-specific products or primer
dimers, a melting analysis was performed from 70 to 95 °C at the end of each run,
with a slope of 0.5 °C/c, and 5 s at each temperature.
Statistical analysis. Data are plotted using violin plots and mean, median, 95% CI
and ranges are shown as appropriate. Where shown, error bars represent standard
deviation of the mean. All statistical analysis was performed with the statistical
software package SPSS version 23 or with GraphPad Prism 8 for macOS (v8.4.2).
Normality was evaluated using the D’Agostino–Pearson test and differences in
parasite numbers in mice and sand fly tissues were tested by non-parametric
(Mann–Whitney U, Mood’s median test) or parametric tests (student’s t test or
ANOVA) depending on data distribution. Time to event analysis was conducted
using the log-rank (Mantel-Cox) test.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Sequence data for L. major MRC-01 and L. major MRC-02 are available from GenBank
(BioProject PRJNA633113: accession numbers SAMN14933143, SAMN14933144 and
SAMN14933145. Parasite genomics data used in compiling Fig. 2 are available from
TriTrypDB (https://tritrypdb.org/tritrypdb/app). Parasites produced under GMP will be
available for clinical assessment of candidate Leishmania vaccines under an appropriate
MTA. Source data and additional data supporting Fig. 6 are provided in Supplementary
Data 1. Source data are provided with this paper.
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